Futura Medical plc (FAMDF)
USD 0.12
(26.32%)
USD 0.12
(26.32%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.73 Million GBP | 27.16% |
| 2022 | 6.87 Million GBP | 17.13% |
| 2021 | 5.86 Million GBP | 100.33% |
| 2020 | 2.92 Million GBP | -73.84% |
| 2019 | 11.19 Million GBP | 54.07% |
| 2018 | 7.26 Million GBP | 39.24% |
| 2017 | 5.21 Million GBP | 10.46% |
| 2016 | 4.72 Million GBP | -23.13% |
| 2015 | 6.14 Million GBP | 72.13% |
| 2014 | 3.57 Million GBP | 23.03% |
| 2013 | 2.9 Million GBP | 14.68% |
| 2012 | 2.53 Million GBP | 12.14% |
| 2011 | 2.25 Million GBP | 54.48% |
| 2010 | 1.46 Million GBP | -7.65% |
| 2009 | 1.58 Million GBP | -31.87% |
| 2008 | 2.32 Million GBP | -11.71% |
| 2007 | 2.63 Million GBP | 24.7% |
| 2006 | 2.1 Million GBP | -10.56% |
| 2005 | 2.35 Million GBP | 38.54% |
| 2004 | 1.7 Million GBP | 12.86% |
| 2003 | 1.5 Million GBP | 16.36% |
| 2002 | 1.29 Million GBP | -3.5% |
| 2001 | 1.34 Million GBP | 242.6% |
| 2000 | 392 Thousand GBP | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2 Million GBP | 0.0% |
| 2024 Q1 | 2 Million GBP | -31.84% |
| 2023 Q1 | 1.43 Million GBP | -64.23% |
| 2023 Q3 | 2.93 Million GBP | 4.71% |
| 2023 Q4 | 2.93 Million GBP | -0.0% |
| 2023 FY | 8.73 Million GBP | 27.16% |
| 2023 Q2 | 2.8 Million GBP | 95.45% |
| 2022 Q4 | 4 Million GBP | 99.39% |
| 2022 Q2 | 2.83 Million GBP | 99.13% |
| 2022 Q1 | 1.42 Million GBP | -63.98% |
| 2022 FY | 6.87 Million GBP | 17.13% |
| 2022 Q3 | 2.01 Million GBP | -29.13% |
| 2021 Q3 | 1.98 Million GBP | 4.85% |
| 2021 Q2 | 1.89 Million GBP | 98.8% |
| 2021 FY | 5.86 Million GBP | 100.33% |
| 2021 Q1 | 950.94 Thousand GBP | -37.56% |
| 2021 Q4 | 3.95 Million GBP | 99.58% |
| 2020 Q2 | 1.38 Million GBP | 98.23% |
| 2020 Q3 | 767.76 Thousand GBP | -44.39% |
| 2020 FY | 2.92 Million GBP | -73.84% |
| 2020 Q4 | 1.52 Million GBP | 98.35% |
| 2020 Q1 | 696.43 Thousand GBP | -88.21% |
| 2019 Q3 | 2.96 Million GBP | -43.79% |
| 2019 FY | 11.19 Million GBP | 54.07% |
| 2019 Q1 | 2.63 Million GBP | 11.09% |
| 2019 Q2 | 5.26 Million GBP | 99.7% |
| 2019 Q4 | 5.9 Million GBP | 99.57% |
| 2018 Q3 | 2.37 Million GBP | 88.51% |
| 2018 FY | 7.26 Million GBP | 39.24% |
| 2018 Q2 | 1.25 Million GBP | -0.0% |
| 2018 Q1 | 1.25 Million GBP | -11.59% |
| 2018 Q4 | 2.37 Million GBP | 0.0% |
| 2017 Q2 | 1.18 Million GBP | -0.0% |
| 2017 Q1 | 1.18 Million GBP | -0.85% |
| 2017 Q4 | 1.42 Million GBP | 0.0% |
| 2017 FY | 5.21 Million GBP | 10.46% |
| 2017 Q3 | 1.42 Million GBP | 20.21% |
| 2016 Q1 | 1.16 Million GBP | -24.9% |
| 2016 FY | 4.72 Million GBP | -23.13% |
| 2016 Q3 | 1.19 Million GBP | 2.4% |
| 2016 Q2 | 1.16 Million GBP | -0.0% |
| 2016 Q4 | 1.19 Million GBP | 0.0% |
| 2015 Q1 | 1.51 Million GBP | 58.51% |
| 2015 Q2 | 1.51 Million GBP | -0.0% |
| 2015 Q4 | 1.55 Million GBP | 0.0% |
| 2015 Q3 | 1.55 Million GBP | 2.3% |
| 2015 FY | 6.14 Million GBP | 72.13% |
| 2014 Q2 | 827.01 Thousand GBP | -0.0% |
| 2014 Q3 | 958.36 Thousand GBP | 15.88% |
| 2014 FY | 3.57 Million GBP | 23.03% |
| 2014 Q4 | 958.36 Thousand GBP | 0.0% |
| 2014 Q1 | 827.01 Thousand GBP | 7.11% |
| 2013 Q3 | 772.11 Thousand GBP | 13.7% |
| 2013 Q2 | 679.1 Thousand GBP | -0.0% |
| 2013 Q1 | 679.1 Thousand GBP | 0.0% |
| 2013 FY | 2.9 Million GBP | 14.68% |
| 2013 Q4 | 772.11 Thousand GBP | 0.0% |
| 2012 FY | 2.53 Million GBP | 12.14% |
| 2011 FY | 2.25 Million GBP | 54.48% |
| 2010 FY | 1.46 Million GBP | -7.65% |
| 2009 FY | 1.58 Million GBP | -31.87% |
| 2008 FY | 2.32 Million GBP | -11.71% |
| 2007 FY | 2.63 Million GBP | 24.7% |
| 2006 FY | 2.1 Million GBP | -10.56% |
| 2005 FY | 2.35 Million GBP | 38.54% |
| 2004 FY | 1.7 Million GBP | 12.86% |
| 2003 FY | 1.5 Million GBP | 16.36% |
| 2002 FY | 1.29 Million GBP | -3.5% |
| 2001 FY | 1.34 Million GBP | 242.6% |
| 2000 FY | 392 Thousand GBP | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | -139.351% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -551.338% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -232.556% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 70.433% |
| GB Sciences, Inc. | 1.42 Million USD | -515.131% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -156.624% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3870.408% |
| Skye Bioscience, Inc. | 13.54 Million USD | 35.501% |
| Zenith Capital Corp. | 8.94 Million USD | 2.292% |
| Agentix Corp. | 1.37 Million USD | -536.993% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -73.303% |
| Biomind Labs Inc. | 994.18 Thousand USD | -778.913% |
| ContraFect Corporation | 56.88 Million USD | 84.64% |
| CSL Limited | 3.44 Billion USD | 99.747% |
| CytoDyn Inc. | 18.05 Million USD | 51.612% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -368.684% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2143.008% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 84.788% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2003.114% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -481.796% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -846.172% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 76.546% |
| SQZ Biotechnologies Company | 85.61 Million USD | 89.794% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -326.513% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 89.931% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -199.633% |
| Mesoblast Limited | 5.9 Million USD | -48.051% |
| Marizyme, Inc. | 19.23 Million USD | 54.584% |
| Genus plc | 147.7 Million USD | 94.084% |
| Pharming Group N.V. | 225.49 Million USD | 96.125% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -4.785% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -490.903% |
| IMV Inc. | 37.7 Million USD | 76.828% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -213.15% |
| MultiCell Technologies, Inc. | 567.42 USD | -1539851.887% |
| ONE Bio Corp. | 6.44 Million USD | -35.601% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 89.833% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 64.645% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -396.568% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -30.068% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 35051.98% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 45.422% |
| Alpha Cognition Inc. | 9.7 Million USD | 9.97% |
| Enzolytics Inc. | 2.17 Million USD | -300.916% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.43% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -736.973% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -263.336% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.941% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -77.677% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3238.604% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -255.881% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -4994.773% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -354.889% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 0.47% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -98.2% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -133.236% |
| Helix BioMedix, Inc. | 1.97 Million USD | -343.096% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1542.598% |
| Q BioMed Inc. | 3.43 Million USD | -154.261% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 19.591% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 91.203% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 61.967% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -376.16% |
| HST Global, Inc. | 140.9 Thousand USD | -6101.25% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -554.32% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -676.773% |
| Halberd Corporation | 74.84 Thousand USD | -11575.256% |
| Resverlogix Corp. | 12.71 Million USD | 31.262% |
| Cell Source, Inc. | 4.32 Million USD | -102.018% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -453.264% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -19.53% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -50057.827% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -254.229% |
| Kadimastem Ltd | 2.41 Million USD | -262.556% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -106.162% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -4714.72% |
| LadRx Corporation | 3.81 Million USD | -129.236% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -846.172% |
| Affymax, Inc. | 39.38 Million USD | 77.814% |
| Itoco Inc. | 919.14 Thousand USD | -850.668% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -680.875% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1475.702% |
| International Stem Cell Corporation | 5.27 Million USD | -65.775% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -128.735% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -34617.291% |
| Qrons Inc. | 643.67 Thousand USD | -1257.512% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -515.442% |
| SYBLEU INC | 160.87 Thousand USD | -5331.509% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -291.86% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1215.963% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -381.082% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -16498.904% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -42853.325% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 75.906% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -440.049% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1087.494% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -180.874% |
| Neutra Corp. | 243.82 Thousand USD | -3483.775% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 49.946% |
| PureTech Health plc | 144.59 Million USD | 93.957% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 57.355% |
| IXICO plc | 4.7 Million USD | -85.638% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 0.671% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 92.579% |
| CSL Limited | 3.89 Billion USD | 99.776% |
| Cellectis S.A. | 97.32 Million USD | 91.021% |